Search for drugs:
Typing the drug name to query
PERAMIVIR
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Cardiac Electrophysiology
- At twice the maximum recommended dose, RAPIVAB did not prolong the QTc interval to any clinically relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
2
24090
Other ADRs
490
38381097
Odds Ratio = 6.504
Drug Property Information
ATC Code(s):
- J05AH03 - peramivir
- J05AH - Neuraminidase inhibitors
- J05A - DIRECT ACTING ANTIVIRALS
- J05 - ANTIVIRALS FOR SYSTEMIC USE
- J - ANTIINFECTIVES FOR SYSTEMIC USE
Active Ingredient:peramivir
Active Ingredient UNII:QW7Y7ZR15U
Drugbank ID:DB06614
PubChem Compound:154234
CTD ID:C414210
CAS Number:330600-85-6
Dosage Form(s):solution
Route(s) Of Administrator:intravenous
Daily Dose:
- 600.0 mg/day J05AH03
Chemical Structure: 
SMILE Code:
[H][C@@]1([C@@H](NC(C)=O)C(CC)CC)[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
[H][C@@]1([C@@H](NC(C)=O)C(CC)CC)[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.